Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5178495
Max Phase: Preclinical
Molecular Formula: C29H38N6O2S
Molecular Weight: 534.73
Associated Items:
ID: ALA5178495
Max Phase: Preclinical
Molecular Formula: C29H38N6O2S
Molecular Weight: 534.73
Associated Items:
Canonical SMILES: CC(=O)Nc1cccc(C(=O)N[C@@H](CCN2[C@@H]3CC[C@H]2C[C@H](n2c(C)nnc2C(C)C)C3)c2cccs2)c1
Standard InChI: InChI=1S/C29H38N6O2S/c1-18(2)28-33-32-19(3)35(28)25-16-23-10-11-24(17-25)34(23)13-12-26(27-9-6-14-38-27)31-29(37)21-7-5-8-22(15-21)30-20(4)36/h5-9,14-15,18,23-26H,10-13,16-17H2,1-4H3,(H,30,36)(H,31,37)/t23-,24+,25-,26-/m0/s1
Standard InChI Key: GDVGEUOSRRTZCI-QYOOZWMWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 534.73 | Molecular Weight (Monoisotopic): 534.2777 | AlogP: 5.46 | #Rotatable Bonds: 9 |
Polar Surface Area: 92.15 | Molecular Species: BASE | HBA: 7 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 8 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 13.93 | CX Basic pKa: 9.02 | CX LogP: 3.03 | CX LogD: 1.40 |
Aromatic Rings: 3 | Heavy Atoms: 38 | QED Weighted: 0.38 | Np Likeness Score: -1.50 |
1. Xie X, Zheng YG, Chen H, Li J, Luo RH, Chen L, Zheng CB, Zhang S, Peng P, Ma D, Yang LM, Zheng YT, Liu H, Wang J.. (2022) Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability., 65 (24.0): [PMID:36472561] [10.1021/acs.jmedchem.2c01383] |
Source(1):